About: Imiquimod suppresses respiratory syncytial virus (RSV) replication via PKA pathway and reduces RSV induced-inflammation and viral load in mice lungs

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Imiquimod suppresses respiratory syncytial virus (RSV) replication via PKA pathway and reduces RSV induced-inflammation and viral load in mice lungs Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Imiquimod suppresses respiratory syncytial virus (RSV) replication via PKA pathway and reduces RSV induced-inflammation and viral load in mice lungs
Creator	Bueno, Carlos Carlos, Alberto Benedetti, Martina Marini, Victoria Salinas, Franco Shayo, Carina Viegas, Mariana Vázquez, Luciana Benedetti, Mercedes Benedetti, V Bueno, Bueno, C Díaz Nebreda, Antonela Díaz Nebreda, Luciana Franco, Maximiliano Gentilini, Gentilini, L Gentilini, Victoria Jodar, Mariana Jodar, Nabaes Marini, M Marini, Martina María, Virginia Nebreda, A Salinas, Antonela Salinas, F Shayo, Soledad, Mercedes Soledad, Nabaes Viegas, Carina Viegas, M Vázquez, Virginia
source	Elsevier; Medline; PMC
abstract	Abstract Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease and bronchiolitis in children, as well as an important cause of morbidity and mortality in elderly and immunocompromised individuals. However, there is no safe and efficacious RSV vaccine or antiviral treatment. Toll Like Receptors (TLR) are important molecular mediators linking innate and adaptive immunity, and their stimulation by cognate agonists has been explored as antiviral agents. Imiquimod is known as a TLR7 agonist, but additionally acts as an antagonist for adenosine receptors. In this study, we demonstrate that imiquimod, but not resiquimod, has direct anti-RSV activity via PKA pathway in HEp-2 and A549 cells, independently of an innate response. Imiquimod restricts RSV infection after viral entry into the host cell, interfering with viral RNA and protein synthesis. Probably as a consequence of these anti-RSV properties, imiquimod displays cytokine modulating activity in RSV infected epithelial cells. Moreover, in a murine model of RSV infection, imiquimod treatment improves the course of acute disease, evidenced by decreased weight loss, reduced RSV lung titers, and attenuated airway inflammation. Consequently, imiquimod represents a promising therapeutic alternative against RSV infection and may inform the development of novel therapeutic targets to control RSV pathogenesis.
has issue date	2020-05-06(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2020.104817
bibo:pmid	32387475
has license	els-covid
sha1sum (hex)	33d14ff5ca29615978c7925403da22600922f9b4
schema:url	https://doi.org/10.1016/j.antiviral.2020.104817
resource representing a document's title	Imiquimod suppresses respiratory syncytial virus (RSV) replication via PKA pathway and reduces RSV induced-inflammation and viral load in mice lungs
has PubMed Central identifier	PMC7202858
has PubMed identifier	32387475
schema:publication	Antiviral Res
resource representing a document's body	covid:33d14ff5ca29615978c7925403da22600922f9b4#body_text
is schema:about of	named entity 'RSV' named entity 'viral load' covid:arg/33d14ff5ca29615978c7925403da22600922f9b4 named entity 'doi' named entity 'viral load' named entity 'RSV' named entity 'inflammation' named entity 'RSV' named entity 'mice' named entity 'viral load' named entity 'inflammation' named entity 'Imiquimod' named entity 'lungs' named entity 'imiquimod' named entity 'A549' named entity 'CREB' named entity 'titrated' named entity 'Mice' named entity 'H&E staining' named entity 'PKA' named entity 'viral RNA' named entity 'RSV' named entity 'pathology' named entity 'DAPI' named entity 'viral load' named entity 'infection' named entity 'antiviral' named entity 'homogenized' named entity 'agonist' named entity 'lysates' named entity 'TLR' named entity 'RSV' named entity 'virus' named entity 'macromolecules' named entity 'HSV-1' named entity 'lung inflammation' named entity 'HEp-2' named entity 'Imiquimod' named entity 'Virus' named entity 'pathogen' named entity 'transcription' named entity 'imiquimod' named entity 'imiquimod' named entity 'cAMP' named entity 'supernatants' named entity 'salt' named entity 'A549 cell' named entity 'sulphate' named entity 'imiquimod' named entity 'A549'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software